Workflow
和邦生物10月20日获融资买入3408.85万元,融资余额5.52亿元

Core Viewpoint - The stock of Hebang Biotechnology experienced a decline of 1.85% on October 20, with a trading volume of 423 million yuan, indicating a challenging market environment for the company [1]. Financing Summary - On October 20, Hebang Biotechnology had a financing buy-in amount of 34.09 million yuan and a financing repayment of 40.44 million yuan, resulting in a net financing outflow of 6.35 million yuan [1]. - The total financing and securities balance for Hebang Biotechnology as of October 20 is 560 million yuan, with the current financing balance of 552 million yuan accounting for 2.95% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low financing level [1]. - In terms of securities lending, on October 20, Hebang Biotechnology repaid 510,700 shares and sold 53,100 shares, with a selling amount of 112,600 yuan based on the closing price of the day. The remaining securities lending volume is 3.94 million shares, with a balance of 8.36 million yuan, which exceeds the 90th percentile level over the past year, indicating a high level of securities lending [1]. Business Performance - As of June 30, the number of shareholders for Hebang Biotechnology is 200,500, a decrease of 2.35% from the previous period, while the average circulating shares per person increased by 2.41% to 44,043 shares [2]. - For the first half of 2025, Hebang Biotechnology reported an operating income of 3.92 billion yuan, a year-on-year decrease of 19.13%, and a net profit attributable to shareholders of 51.77 million yuan, down 73.07% year-on-year [2]. Dividend Information - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, among the top ten circulating shareholders of Hebang Biotechnology, the Southern CSI 500 ETF ranks as the fifth largest shareholder with 92.27 million shares, an increase of 12.80 million shares compared to the previous period. Conversely, Hong Kong Central Clearing Limited, the sixth largest shareholder, holds 73.19 million shares, a decrease of 50.63 million shares from the previous period [3].